# Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting Canonical URL: https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-poster-presentation-highlights-for-nxp900-from-the-2025-aacr-meeting Ticker: NVCT Company: Nuvectis Pharma Source: Nuvectis Pharma Published: 2025-04-29 16:25 EST Original Source URL: https://www.pressviewer.com ## Summary

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerat ## Article Body Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters... ## Recent Company News - 2025-09-04 07:30 EST — [Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference) — Source: Nuvectis Pharma - 2025-08-11 16:30 EST — [Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-the-initiation-of-the-phase-1b-program-for-nxp900) — Source: Nuvectis Pharma - 2025-08-05 07:30 EST — [Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-and-business-highlights) — Source: Nuvectis Pharma - 2025-07-31 07:45 EST — [Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-final-clinical-data-update-from-the-nxp800-phase-1b-study-in-ovarian-cancer-and-reports-completion-of-the-nxp900-phase-1a-dose-escalation-study) — Source: Nuvectis Pharma - 2025-07-08 08:00 EST — [Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-successful-completion-of-a-drug-drug-interaction-study-in-healthy-volunteers-supporting-nxp900-s-potential-as-a-combination-partner-with-leading-therapies) — Source: Nuvectis Pharma ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)